{"id":7510,"date":"2026-03-06T15:05:01","date_gmt":"2026-03-06T14:05:01","guid":{"rendered":"https:\/\/value-dossier.com\/?page_id=7510"},"modified":"2026-03-06T15:05:01","modified_gmt":"2026-03-06T14:05:01","slug":"amnog-negotiation-guide-2","status":"publish","type":"page","link":"https:\/\/value-dossier.com\/en\/amnog-negotiation-guide-2\/","title":{"rendered":"AMNOG Negotiation Guide"},"content":{"rendered":"\n<section class=\"wrap_outer intro-alternative no-spacing\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"intro__text\">\n            <div class=\"okd-text\">\n                                    <div class=\"badge\">AMNOG<\/div>\n                                <h1>AMNOG negotiation guide<\/h1>\n                                    <div class=\"usps\">\n                        <ul>\n                                                            <li>Calculate reimbursement realistically<\/li>\n                                                            <li>Identify negotiation options<\/li>\n                                                            <li>Estimate negotiation range<\/li>\n                                                    <\/ul>\n                    <\/div>\n                                            <\/div>\n        <\/div>\n\n    <\/div>\n    <div class=\"intro__visual\">\n        <div class=\"wrap_inner\">\n\n            <div class='fluentform ff-default fluentform_wrapper_9 ffs_default_wrap'><form data-form_id=\"9\" id=\"fluentform_9\" class=\"frm-fluent-form fluent_form_9 ff-el-form-top ff_form_instance_9_1 ff-form-loading ff-form-has-steps ffs_default\" data-form_instance=\"ff_form_instance_9_1\" method=\"POST\" ><fieldset  style=\"border: none!important;margin: 0!important;padding: 0!important;background-color: transparent!important;box-shadow: none!important;outline: none!important; min-inline-size: 100%;\">\n                    <legend class=\"ff_screen_reader_title\" style=\"display: block; margin: 0!important;padding: 0!important;height: 0!important;text-indent: -999999px;width: 0!important;overflow:hidden;\">AMNOG Formular_2025<\/legend><input type='hidden' name='__fluent_form_embded_post_id' value='7510' \/><input type=\"hidden\" id=\"_fluentform_9_fluentformnonce\" name=\"_fluentform_9_fluentformnonce\" value=\"af72cc83aa\" \/><input type=\"hidden\" name=\"_wp_http_referer\" value=\"\/en\/wp-json\/wp\/v2\/pages\/7510\" \/><div class='ff-step-container' data-name=\"step_start-9_44\" data-disable_auto_focus=\"no\" data-enable_auto_slider=\"no\" data-enable_step_data_persistency=\"no\" data-enable_step_page_resume=\"no\" data-animation_type=\"slide\" ><div class='ff-step-header'><div class='ff-el-progress-status' aria-live='polite'><\/div>\n            <div class='ff-el-progress'>\n                <div role='progressbar'  class='ff-el-progress-bar'><span><\/span><\/div>\n            <\/div>\n            <ul style='display: none' class='ff-el-progress-title'>\n                <li><\/li><li><\/li><li><\/li>\n            <\/ul><\/div><span class='ff_step_start'><\/span><div class='ff-step-body'><div class=\"fluentform-step active\" data-name=\"step_start-9_44\" data-disable_auto_focus=\"no\" data-enable_auto_slider=\"no\" data-enable_step_data_persistency=\"no\" data-enable_step_page_resume=\"no\" data-animation_type=\"slide\" ><div class='ff-el-group'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"What kind of product will be negotiated?\">What kind of product will be negotiated?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_bc1a43b7803249d5ee30d7338990efb4'><input  type=\"radio\" name=\"input_radio\" data-name=\"input_radio\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Arzneimittel\"  id='input_radio_bc1a43b7803249d5ee30d7338990efb4' aria-label='Medicinal product' aria-invalid='false' aria-required=true> <span>Medicinal product<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_967ad4e8bf180f95663430346c52268d'><input  type=\"radio\" name=\"input_radio\" data-name=\"input_radio\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Arzneimittel zur Behandlung seltener Leiden\"  id='input_radio_967ad4e8bf180f95663430346c52268d' aria-label='Orphan drug' aria-invalid='false' aria-required=true> <span>Orphan drug<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_a36fb8314c1c2ab4bb722e3329589b55'><input  type=\"radio\" name=\"input_radio\" data-name=\"input_radio\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Reserveantibiotikum\"  id='input_radio_a36fb8314c1c2ab4bb722e3329589b55' aria-label='Reserve antibiotic' aria-invalid='false' aria-required=true> <span>Reserve antibiotic<\/span><\/label><\/div><\/div><\/div><div class='step-nav ff_step_nav_last'><button style='float: left;'  type='button' data-action='prev' class='ff-btn ff-btn-prev ff-btn-secondary' aria-label='Back'>Back<\/button><button style='float: right;'  type='button' data-action='next' class='ff-float-right ff-btn ff-btn-next ff-btn-secondary' aria-label='Next'>Next<\/button><\/div><\/div><div style='display: none;' class=\" fluentform-step\" data-name=\"form_step-9_1\" ><div data-name=\"ff_cn_id_1\"  class='ff-t-container ff-column-container ff_columns_total_1 '><div class='ff-t-cell ff-t-column-1' style='flex-basis: 100%;'><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"Is there a comparative therapy?\">Is there a comparative therapy?<\/label><div class=\"ff-el-tooltip\" data-content=\"EN: According to Section 35a (1) SGB V, the additional benefit of an orphan drug is considered proven with the authorisation. A comparison with an appropriate comparator therapy is therefore not necessary as part of the benefit assessment. However, comparable medicinal products can still be used as reference values within the price negotiations.  \"><svg width=\"16\" height=\"16\" viewBox=\"0 0 25 25\"><path d=\"m329 393l0-46c0-2-1-4-2-6-2-2-4-3-7-3l-27 0 0-146c0-3-1-5-3-7-2-1-4-2-7-2l-91 0c-3 0-5 1-7 2-1 2-2 4-2 7l0 46c0 2 1 5 2 6 2 2 4 3 7 3l27 0 0 91-27 0c-3 0-5 1-7 3-1 2-2 4-2 6l0 46c0 3 1 5 2 7 2 1 4 2 7 2l128 0c3 0 5-1 7-2 1-2 2-4 2-7z m-36-256l0-46c0-2-1-4-3-6-2-2-4-3-7-3l-54 0c-3 0-5 1-7 3-2 2-3 4-3 6l0 46c0 3 1 5 3 7 2 1 4 2 7 2l54 0c3 0 5-1 7-2 2-2 3-4 3-7z m182 119c0 40-9 77-29 110-20 34-46 60-80 80-33 20-70 29-110 29-40 0-77-9-110-29-34-20-60-46-80-80-20-33-29-70-29-110 0-40 9-77 29-110 20-34 46-60 80-80 33-20 70-29 110-29 40 0 77 9 110 29 34 20 60 46 80 80 20 33 29 70 29 110z\" transform=\"scale(0.046875 0.046875)\"><\/path><\/svg><\/div><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_1_3d322e72977be7a467693c55c41fbc2e'><input  type=\"radio\" name=\"input_radio_1\" data-name=\"input_radio_1\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Ja, die Vergleichstherapie ist patentgesch\u00fctzt\"  id='input_radio_1_3d322e72977be7a467693c55c41fbc2e' aria-label='Yes, patent-protected comparative therapy' aria-invalid='false' aria-required=true> <span>Yes, patent-protected comparative therapy<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_1_3272f935004162663c1d95a09661265f'><input  type=\"radio\" name=\"input_radio_1\" data-name=\"input_radio_1\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Ja, die Vergleichstherapie ist generisch\"  id='input_radio_1_3272f935004162663c1d95a09661265f' aria-label='Yes, the comparative therapy is generic' aria-invalid='false' aria-required=true> <span>Yes, the comparative therapy is generic<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_1_076ea3f796f421d32ed2720c557f6ce2'><input  type=\"radio\" name=\"input_radio_1\" data-name=\"input_radio_1\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\u00fctztes vergleichbares Arzneimittel verf\u00fcgbar)\"  id='input_radio_1_076ea3f796f421d32ed2720c557f6ce2' aria-label='Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\u00fctztes vergleichbares Arzneimittel verf\u00fcgbar)' aria-invalid='false' aria-required=true> <span>Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\u00fctztes vergleichbares Arzneimittel verf\u00fcgbar)<\/span><\/label><\/div><\/div><\/div><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"Did the patent protected comparative therapy undergo an AMNOG benefit assessment?\">Did the patent protected comparative therapy undergo an AMNOG benefit assessment?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_3_e25ae6c2b1facb979b0b803f1ca2d0b0'><input  type=\"radio\" name=\"input_radio_3\" data-name=\"input_radio_3\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Ja\"  id='input_radio_3_e25ae6c2b1facb979b0b803f1ca2d0b0' aria-label='Yes' aria-invalid='false' aria-required=true> <span>Yes<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_3_4cfd075bf20a607a00b6f92687f6577c'><input  type=\"radio\" name=\"input_radio_3\" data-name=\"input_radio_3\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Nein\"  id='input_radio_3_4cfd075bf20a607a00b6f92687f6577c' aria-label='No' aria-invalid='false' aria-required=true> <span>No<\/span><\/label><\/div><\/div><\/div><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"What is the extend of the expected added benefit?\">What is the extend of the expected added benefit?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_2_a286a7d7ef16aeb07a426cbed1901bb2'><input  type=\"radio\" name=\"input_radio_2\" data-name=\"input_radio_2\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Erheblich\"  id='input_radio_2_a286a7d7ef16aeb07a426cbed1901bb2' aria-label='Major' aria-invalid='false' aria-required=true> <span>Major<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_2_8aa68104b173687d5b225fc01ad02c78'><input  type=\"radio\" name=\"input_radio_2\" data-name=\"input_radio_2\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Betr\u00e4chtlich\"  id='input_radio_2_8aa68104b173687d5b225fc01ad02c78' aria-label='Considerable' aria-invalid='false' aria-required=true> <span>Considerable<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_2_4cebb272163d5bfbf77d9b2f1416db70'><input  type=\"radio\" name=\"input_radio_2\" data-name=\"input_radio_2\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Gering\"  id='input_radio_2_4cebb272163d5bfbf77d9b2f1416db70' aria-label='Minor' aria-invalid='false' aria-required=true> <span>Minor<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_2_2b5f41a6761a39527d4bdd336e5f54a6'><input  type=\"radio\" name=\"input_radio_2\" data-name=\"input_radio_2\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Nicht-quantifizierbar\"  id='input_radio_2_2b5f41a6761a39527d4bdd336e5f54a6' aria-label='Non-quantifiable' aria-invalid='false' aria-required=true> <span>Non-quantifiable<\/span><\/label><\/div><\/div><\/div><\/div><\/div><div data-name=\"ff_cn_id_2\"  class='ff-t-container ff-column-container ff_columns_total_1 '><div class='ff-t-cell ff-t-column-1' style='flex-basis: 100%;'><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"What is the extend of the expected added benefit?\">What is the extend of the expected added benefit?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_4_f752fb25bcbafa0e8d3b034a5b80d9b0'><input  type=\"radio\" name=\"input_radio_4\" data-name=\"input_radio_4\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Erheblich\"  id='input_radio_4_f752fb25bcbafa0e8d3b034a5b80d9b0' aria-label='Major' aria-invalid='false' aria-required=true> <span>Major<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_4_fdb41332c8d820fe77abd61611b4b1b0'><input  type=\"radio\" name=\"input_radio_4\" data-name=\"input_radio_4\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Betr\u00e4chtlich\"  id='input_radio_4_fdb41332c8d820fe77abd61611b4b1b0' aria-label='Considerable' aria-invalid='false' aria-required=true> <span>Considerable<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_4_151e6ee5b88c4238db3df207f02e62cf'><input  type=\"radio\" name=\"input_radio_4\" data-name=\"input_radio_4\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Gering\"  id='input_radio_4_151e6ee5b88c4238db3df207f02e62cf' aria-label='Minor' aria-invalid='false' aria-required=true> <span>Minor<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_4_18bb39492341982d516ba8c1d5ad3b01'><input  type=\"radio\" name=\"input_radio_4\" data-name=\"input_radio_4\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"kein Zusatznutzen\"  id='input_radio_4_18bb39492341982d516ba8c1d5ad3b01' aria-label='No added benefit' aria-invalid='false' aria-required=true> <span>No added benefit<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_4_33c1b7b70609b85f5d1ff1393201183e'><input  type=\"radio\" name=\"input_radio_4\" data-name=\"input_radio_4\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Kein oder unvollst\u00e4ndiges Dossier eingereicht\"  id='input_radio_4_33c1b7b70609b85f5d1ff1393201183e' aria-label='No or incomplete dossier submitted' aria-invalid='false' aria-required=true> <span>No or incomplete dossier submitted<\/span><\/label><\/div><\/div><\/div><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"Is there a type 2 reference price group?\">Is there a type 2 reference price group?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_6_15df4afeb05c77a499e831153d059756'><input  type=\"radio\" name=\"input_radio_6\" data-name=\"input_radio_6\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Ja\"  id='input_radio_6_15df4afeb05c77a499e831153d059756' aria-label='Yes' aria-invalid='false' aria-required=true> <span>Yes<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_6_0ca0a044205c5894963a613fc8855004'><input  type=\"radio\" name=\"input_radio_6\" data-name=\"input_radio_6\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Nein\"  id='input_radio_6_0ca0a044205c5894963a613fc8855004' aria-label='No' aria-invalid='false' aria-required=true> <span>No<\/span><\/label><\/div><\/div><\/div><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"What is the type of appropriate comparative therapy?\">What is the type of appropriate comparative therapy?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_5_1c69940ad3c116b4595b44977b5fe2fe'><input  type=\"radio\" name=\"input_radio_5\" data-name=\"input_radio_5\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Patentgesch\u00fctzte zweckm\u00e4\u00dfige Vergleichstherapie\"  id='input_radio_5_1c69940ad3c116b4595b44977b5fe2fe' aria-label='Patent-protected appropriate comparative therapy' aria-invalid='false' aria-required=true> <span>Patent-protected appropriate comparative therapy<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_5_ecad62031e2f511ff4892ceff5541f46'><input  type=\"radio\" name=\"input_radio_5\" data-name=\"input_radio_5\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Generische zweckm\u00e4\u00dfige Vergleichstherapie\"  id='input_radio_5_ecad62031e2f511ff4892ceff5541f46' aria-label='Generic appropriate comparative therapy' aria-invalid='false' aria-required=true> <span>Generic appropriate comparative therapy<\/span><\/label><\/div><\/div><\/div><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"In case of a patent-protected comparative therapy: Did the studies which are relevant for the assessment include more 5 % or more German patients?\">In case of a patent-protected comparative therapy: Did the studies which are relevant for the assessment include more 5 % or more German patients?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_10_306109fbcd92ba49721c626ff78e3120'><input  type=\"radio\" name=\"input_radio_10\" data-name=\"input_radio_10\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Ja\"  id='input_radio_10_306109fbcd92ba49721c626ff78e3120' aria-label='Yes' aria-invalid='false' aria-required=true> <span>Yes<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_10_8f585b64dca59cbffae4f70ef912c30d'><input  type=\"radio\" name=\"input_radio_10\" data-name=\"input_radio_10\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Nein\"  id='input_radio_10_8f585b64dca59cbffae4f70ef912c30d' aria-label='No' aria-invalid='false' aria-required=true> <span>No<\/span><\/label><\/div><\/div><\/div><div class='ff-el-group has-conditions'><div class=\"ff-el-input--label ff-el-is-required asterisk-right\"><label   aria-label=\"Did the patent protected comparative therapy undergo an AMNOG benefit assessment?\">Did the patent protected comparative therapy undergo an AMNOG benefit assessment?<\/label><\/div><div class='ff-el-input--content'><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_7_5c9c0ecf704013a82908e4b5c66c3b38'><input  type=\"radio\" name=\"input_radio_7\" data-name=\"input_radio_7\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Ja\"  id='input_radio_7_5c9c0ecf704013a82908e4b5c66c3b38' aria-label='Yes' aria-invalid='false' aria-required=true> <span>Yes<\/span><\/label><\/div><div class='ff-el-form-check ff-el-form-check-'><label class='ff-el-form-check-label' for='input_radio_7_5df98a5f541435132f062aa86e2a9f18'><input  type=\"radio\" name=\"input_radio_7\" data-name=\"input_radio_7\" class=\"ff-el-form-check-input ff-el-form-check-radio\" value=\"Nein\"  id='input_radio_7_5df98a5f541435132f062aa86e2a9f18' aria-label='No' aria-invalid='false' aria-required=true> <span>No<\/span><\/label><\/div><\/div><\/div><\/div><\/div><div class='step-nav ff_step_nav_last'><button style='float: left;'  type='button' data-action='prev' class='ff-btn ff-btn-prev ff-btn-secondary' aria-label='Back'>Back<\/button><button style='float: right;'  type='button' data-action='next' class='ff-float-right ff-btn ff-btn-next ff-btn-secondary' aria-label='Next'>Next<\/button><\/div><\/div><div style='display: none;' class=\" fluentform-step\" data-name=\"form_step-9_2\" ><div data-name=\"ff_cn_id_3\"  class='ff-t-container ff-column-container ff_columns_total_1 '><div class='ff-t-cell ff-t-column-1' style='flex-basis: 100%;'><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_3\" ><h2>Reserve antibiotic<strong><br><\/strong><\/h2>\n<p>For a reserve antibiotic the launch price does not need to be negotiated. The price will probably be negotiated on the level of the hospitals. <\/p><\/div><\/div><\/div><div data-name=\"ff_cn_id_4\"  class='ff-t-container ff-column-container ff_columns_total_1 '><div class='ff-t-cell ff-t-column-1' style='flex-basis: 100%;'><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_4\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Generic<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>\n<p>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/p>\n<\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_5\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Not applicable<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<sup>1<\/sup><em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>\n<p>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/p>\n<\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_6\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Not applicable<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<sup>1<\/sup><em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_7\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Not applicable<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<sup>1<\/sup><em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_8\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Not applicable<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Non-quantifiable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<sup>1<\/sup><em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_9\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Generic<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup> <em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_10\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Generic<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_11\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Generic<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Non-quantifiable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_12\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>\n<p>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/p>\n<\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_13\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_14\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_15\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Non-quantifiable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_16\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_17\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_18\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_19\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Type of Product<\/td>\n<td>Orphan drug<\/td>\n<\/tr>\n<tr>\n<td>Potential comparative therapy<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>Comparative therapy was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Non-quantifiable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest comparator &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>\n<p>Starting position of the pharmaceutical company = launch price<\/p>\n<p>Starting position of the statutory health insurance = price of the cheapest comparator<\/p>\n<p>The negotiated premium price generally falls within the upper and lower limits displayed.<\/p>\n<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_20\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No added benefit<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<\/td>\n<td><span style=\"color: #006ab3\">Fix amount<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_21\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No or incomplete dossier submitted<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">Reference price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_22\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No added benefit<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Generic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<\/td>\n<td><span style=\"color: #006ab3\"><b>\u2264<\/b> Price of the ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_23\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No or incomplete dossier submitted<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Generic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\">&lt; Price of the ACT<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_24\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No added benefit<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; 10 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_25\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No or incomplete dossier submitted<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; 10 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_26\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No or incomplete dossier submitted<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price in the first 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>&lt;<\/b><\/span><\/span> Price of the ACT<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Negotiable premium price after 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; 10 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>3<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>If 5 % or more German patients are included in the studies relevant to the evaluation, the strict AMNOG guidelines introduced by the SHI Financial Stabilization Act are suspended. The premium price is initially valid for 3 years. If the pharmaceutical company proves that an active research department and active research projects exist in Germany, the negotiated reimbursement amount can remain valid beyond the 3 years. However, if there is no active research department and research projects in Germany, the reimbursement amount must be renegotiated after 3 years, taking into account the strict AMNOG guidelines.   <\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_27\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>no added benefit<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price for the first 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Negotiable premium price after 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; 10 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>3<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>If 5 % or more German patients are included in the studies relevant to the evaluation, the strict AMNOG guidelines introduced by the SHI Financial Stabilization Act are suspended. The premium price is initially valid for 3 years. If the pharmaceutical company proves that an active research department and active research projects exist in Germany, the negotiated reimbursement amount can remain valid beyond the 3 years. However, if there is no active research department and research projects in Germany, the reimbursement amount must be renegotiated after 3 years, taking into account the strict AMNOG guidelines.   <\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_28\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No added benefit<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; (10 % + 15 %)<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_29\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No or incomplete dossier submitted<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<em>\n<\/em><\/td><br><td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; (10 % + 15 %)<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_30\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No or incomplete dossier submitted<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price in the first 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; 15 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Negotiable premium price after 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; (10 % + 15 %)<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_31\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>No added benefit<\/td>\n<\/tr>\n<tr>\n<td>Reference price group type 2<\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price in the first 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; 15 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Negotiable premium price after 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><span class=\"ILfuVd\" lang=\"de\"><span class=\"hgKElc\"><b>\u2264<\/b><\/span><\/span> Price of the ACT &#8211; (10 % + 15 %)<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>3<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>If 5 % or more German patients are included in the studies relevant to the evaluation, the strict AMNOG guidelines introduced by the SHI Financial Stabilization Act are suspended. The premium price is initially valid for 3 years. If the pharmaceutical company proves that an active research department and active research projects exist in Germany, the negotiated reimbursement amount can remain valid beyond the 3 years. However, if there is no active research department and research projects in Germany, the reimbursement amount must be renegotiated after 3 years, taking into account the strict AMNOG guidelines.   <\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_32\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Generic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_33\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price for the first 3 years &#8211; upper limit<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Negotiable premium price for the first 3 years &#8211; lower limit<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Negotiable premium price after 3 years<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><b>\u2264<\/b> Price of the cheapest ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>3<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>If 5 % or more German patients are included in the studies relevant to the evaluation, the strict AMNOG guidelines introduced by the SHI Financial Stabilization Act are suspended. The premium price is initially valid for 3 years. If the pharmaceutical company proves that an active research department and active research projects exist in Germany, the negotiated reimbursement amount can remain valid beyond the 3 years. However, if there is no active research department and research projects in Germany, the reimbursement amount must be renegotiated after 3 years, taking into account the strict AMNOG guidelines.   <\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_34\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>Yes<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\"><b>\u2264<\/b> Price of the cheapest ACT &#8211; 15 %<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>3<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>If 5 % or more German patients are included in the studies relevant to the evaluation, the strict AMNOG guidelines introduced by the SHI Financial Stabilization Act are suspended. The premium price is initially valid for 3 years. If the pharmaceutical company proves that an active research department and active research projects exist in Germany, the negotiated reimbursement amount can remain valid beyond the 3 years. However, if there is no active research department and research projects in Germany, the reimbursement amount must be renegotiated after 3 years, taking into account the strict AMNOG guidelines.   <\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_35\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<\/td>\n<td><span style=\"color: #006ab3\"><b>\u2264<\/b> Price of the cheapest ACT<br><\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_36\" ><h2>Summary<\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Minor<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>5 % or more German patients<sup>1<\/sup><\/td>\n<td>No<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Result<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Negotiable premium price<\/td>\n<td><span style=\"color: #006ab3\"><b>\u2264<\/b> Price of the cheapest ACT &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>2<\/sup><\/td>\n<td><span style=\"color: #006ab3\">Possible<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>In regard to the population of the studies relevant for the assessment.<\/li>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_37\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Generic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_38\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Generic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_39\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_40\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT &#8211; 15 %<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_41\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Major<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><div class='ff-el-group  ff-custom_html has-conditions' tabindex='-1' data-name=\"custom_html-9_42\" ><h2>Summary <\/h2>\n<table>\n<tbody>\n<tr>\n<td>Product type<\/td>\n<td>Medicinal product<\/td>\n<\/tr>\n<tr>\n<td>Expected extend of the added benefit<\/td>\n<td>Considerable<\/td>\n<\/tr>\n<tr>\n<td>Appropriate comparative therapy (ACT)<\/td>\n<td>Patent-protected<\/td>\n<\/tr>\n<tr>\n<td>ACT was subjected to AMNOG<\/td>\n<td>Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<h3>Negotiable premium price<\/h3>\n<table>\n<tbody>\n<tr>\n<td>Upper limit<\/td>\n<td><span style=\"color: #006ab3\">&lt; Launch price<\/span><\/td>\n<\/tr>\n<tr>\n<td>Lower limit<\/td>\n<td><span style=\"color: #006ab3\">&gt; Price of the cheapest ACT<\/span><\/td>\n<\/tr>\n<tr>\n<td>Additional 20 % combination rebate possible<sup>1<\/sup><\/td>\n<td><span style=\"color: #3fa34d\">Unlikely<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<ol>\n<li>Note combination rebate: In accordance with Section 130e SGB V, a 20 % combination rebate applies to new active ingredients if they are dispensed at the expense of the health insurance fund in a combination with other new active ingredients specified by the Federal Joint Committee. The combination discount is only removed if the combination can show at least a considerable additional benefit. <\/li>\n<\/ol><\/div><\/div><\/div><div class='ff-el-group ff-text-left  has-conditions ff_submit_btn_wrapper ff_submit_btn_wrapper_custom'><button class=\"ff-btn ff-btn-submit ff-btn-md ff_btn_style wpf_has_custom_css\" type=\"submit\" name=\"custom_submit_button-9_43\" data-name=\"custom_submit_button-9_43\"  aria-label=\"Submit\">Submit<\/button><style>form.fluent_form_9 .wpf_has_custom_css.ff-btn-submit { background-color:#1a7efb;border-color:#1a7efb;color:#ffffff;min-width:100%; }form.fluent_form_9 .wpf_has_custom_css.ff-btn-submit:hover { background-color:#ffffff;border-color:#1a7efb;color:#1a7efb;min-width:100%; } <\/style><\/div>        <div class=\"ff-step-t-container ff-inner_submit_container ff-column-container ff_columns_total_2\">\n            <div class=\"ff-t-cell ff-t-column-1\"><div class='step-nav ff_step_nav_last'><button style='float: left;'  type='button' data-action='prev' class='ff-btn ff-btn-prev ff-btn-secondary' aria-label='Zur\u00fcck'>Zur\u00fcck<\/button><\/div><\/div>\n            <div class=\"ff-t-cell ff-t-column-2\">\n                            <\/div>\n        <\/div>\n        <\/div><\/div><\/div>\n        <\/fieldset><\/form><div id='fluentform_9_errors' class='ff-errors-in-stack ff_form_instance_9_1 ff-form-loading_errors ff_form_instance_9_1_errors'><\/div><\/div>            <script type=\"text\/javascript\">\n                window.fluent_form_ff_form_instance_9_1 = {\"id\":\"9\",\"settings\":{\"layout\":{\"labelPlacement\":\"top\",\"helpMessagePlacement\":\"with_label\",\"errorMessagePlacement\":\"inline\",\"cssClassName\":\"\",\"asteriskPlacement\":\"asterisk-right\"},\"restrictions\":{\"denyEmptySubmission\":{\"enabled\":false}}},\"form_instance\":\"ff_form_instance_9_1\",\"form_id_selector\":\"fluentform_9\",\"rules\":{\"input_radio\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_1\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_3\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_2\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_4\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_6\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_5\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_10\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}},\"input_radio_7\":{\"required\":{\"value\":true,\"message\":\"This field is required\",\"global_message\":\"Dieses Feld ist erforderlich\",\"global\":true}}},\"debounce_time\":300,\"conditionals\":{\"input_radio_1\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_3\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Keine Vergleichstherapie, aber ein patentgesch\\u00fctztes vergleichbares Arzneimittel\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_2\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_1\",\"value\":\"Nicht zutreffend (z. B. keine Vergleichstherapie verf\\u00fcgbar)\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist generisch\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\\u00fctztes vergleichbares Arzneimittel verf\\u00fcgbar)\",\"operator\":\"\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_4\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_6\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_5\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Erheblich\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"Gering\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"Nicht-quantifizierbar\",\"operator\":\"=\"},{\"field\":\"input_radio_6\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_10\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"Erheblich\",\"operator\":\"!=\"},{\"field\":\"input_radio_4\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"!=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"input_radio_7\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_3\":{\"type\":\"any\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Reserveantibiotikum\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_4\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist generisch\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Erheblich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_5\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\\u00fctztes vergleichbares Arzneimittel verf\\u00fcgbar)\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Erheblich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_6\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\\u00fctztes vergleichbares Arzneimittel verf\\u00fcgbar)\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_7\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\\u00fctztes vergleichbares Arzneimittel verf\\u00fcgbar)\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Gering\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_8\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Nicht zutreffend (z. B. keine Vergleichstherapie oder patentgesch\\u00fctztes vergleichbares Arzneimittel verf\\u00fcgbar)\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Nicht-quantifizierbar\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_9\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist generisch\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_10\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist generisch\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Gering\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_11\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist generisch\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Nicht-quantifizierbar\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_12\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Erheblich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_13\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_14\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Gering\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_15\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Nicht-quantifizierbar\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_16\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Erheblich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_17\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_18\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Gering\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_19\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio_1\",\"value\":\"Ja, die Vergleichstherapie ist patentgesch\\u00fctzt\",\"operator\":\"=\"},{\"field\":\"input_radio_3\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_2\",\"value\":\"Nicht-quantifizierbar\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_20\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_6\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_21\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel\",\"operator\":\"=\"},{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"},{\"field\":\"input_radio_6\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_22\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Generische zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_23\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Generische zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_24\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_25\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_26\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_27\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_28\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_29\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_30\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Kein oder unvollst\\u00e4ndiges Dossier eingereicht\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_31\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"kein Zusatznutzen\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_32\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Gering\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Generische zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_33\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Gering\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_34\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Gering\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Ja\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_35\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Gering\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_36\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Gering\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_10\",\"value\":\"Nein\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_37\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Erheblich\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Generische zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_38\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Generische zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_39\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Erheblich\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_40\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Nein\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_41\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Erheblich\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_html-9_42\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio_4\",\"value\":\"Betr\\u00e4chtlich\",\"operator\":\"=\"},{\"field\":\"input_radio_5\",\"value\":\"Patentgesch\\u00fctzte zweckm\\u00e4\\u00dfige Vergleichstherapie\",\"operator\":\"=\"},{\"field\":\"input_radio_7\",\"value\":\"Ja\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]},\"custom_submit_button-9_43\":{\"type\":\"all\",\"status\":true,\"conditions\":[{\"field\":\"input_radio\",\"value\":\"Arzneimittel\",\"operator\":\"=\"},{\"field\":\"input_radio\",\"value\":\"Arzneimittel zur Behandlung seltener Leiden\",\"operator\":\"=\"},{\"field\":\"input_radio\",\"value\":\"Reserveantibiotikum\",\"operator\":\"=\"}],\"condition_groups\":[{\"rules\":[{\"field\":\"\",\"value\":\"\",\"operator\":\"\"}],\"title\":\"\",\"isEditingTitle\":false,\"isPreviewOpen\":false,\"isGroupOpen\":true}]}}};\n                            <\/script>\n            \n        <\/div>\n    <\/div>\n<\/section>\n\n\n<section class=\"wrap_outer outro no-spacing background-none\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"outro__text\">\n            <div class=\"okd-text\">\n                <h2>Your <strong>compass<\/strong> in the AMNOG process<\/h2>\n<p>The AMNOG price calculator provides you with an initial indication of the possible reimbursement price for your product. Let us take the next step together \u2013 we will support you with strategy, dossier and negotiation. <\/p>\n            <\/div>\n            <div class=\"outro__contact\">\n                                    <a class=\"button\" href=\"https:\/\/value-dossier.com\/en\/contact\/\" target=\"_self\">Get in touch<\/a>\n                                                    <a href=\"tel:+49 6173 \/ 39 41 0 16\" class=\"button button-tertiary button-phone\">+49 6173 \/ 39 41 0 16<\/a>\n                            <\/div>\n        <\/div>\n\n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-7510","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/7510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/comments?post=7510"}],"version-history":[{"count":1,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/7510\/revisions"}],"predecessor-version":[{"id":7511,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/pages\/7510\/revisions\/7511"}],"wp:attachment":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media?parent=7510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}